part 3 Biochemistry of Monosaccharides and Glycoproteins

Monosaccharides and Their Activated Forms:

  • Glucose:

    • Primary energy source for cells (essential for cellular metabolism).

    • Activated form: UDP-Glc (uridine diphosphate glucose).

    • Role: Biosynthesis of glycoproteins and glycolipids (important for cell signaling and structural integrity).

  • Galactose:

    • Found in dairy products.

    • Activated form: UDP-Gal (uridine diphosphate galactose).

    • Role: Formation of glycosaminoglycans (GAGs), glycoproteins, and glycolipids (vital for cellular communication, adhesion, and tissue hydration).

  • Mannose:

    • Present in many plant polysaccharides.

    • Activated form: GDP-Man (guanosine diphosphate mannose).

    • Role: Important in glycoprotein synthesis (especially important in lysosomal targeting).

  • Fucose:

    • Activated form: GDP-Fuc (guanosine diphosphate fucose).

    • Role: Added to proteins and lipids during glycosylation, influencing cell-cell interactions and immune response modulation (impacting immune system recognition).

  • N-acetylglucosamine (GlcNAc):

    • Activated form: UDP-GlcNAc (uridine diphosphate N-acetylglucosamine).

    • Role: Component of chitin and peptidoglycan (maintaining cell structure), structural integrity, and signaling pathways (influencing growth and differentiation).

  • N-acetylgalactosamine (GalNAc):

    • Activated form: UDP-GalNAc (uridine diphosphate N-acetylgalactosamine).

    • Role: Involved in biosynthesis of glycoproteins and glycolipids (especially in mucins, maintaining barrier functions).

  • Glucuronic acid:

    • Activated form: UDP-GlcUA (uridine diphosphate glucuronic acid).

    • Role: Detoxifying drugs and metabolites by forming glucuronides (increasing water solubility for excretion).

  • Sialic Acid (NANA):

    • Activated form: CMP-NANA (cytidine monophosphate N-acetylneuraminic acid).

    • Role: Terminal modification of glycoproteins and glycolipids (affecting overall function and cellular interactions).

Activated Monosaccharide Synthesis:

  • Production of Amino Sugars:

    • Fructose-6-P (a fructose phosphate) converts to Gluosamine-1-P (an amino sugar precursor).

    • UDP-Gluosamine (activated form) is formed from Gluosamine-1-P and UTP (uridine triphosphate), releasing pyrophosphate (PPi).

    • Key products include UDP-GlcNAc (produced from GlcNAc-1-P), Sialic Acid-9-P (CMP-Sialic Acid), and GDP-Man (guanosine diphosphate mannose).

Synthesis of GAGs:

  • Core Protein Synthesis:

    • Synthesized in the rough endoplasmic reticulum (ER).

    • Transported into the ER lumen, where glycosylation (addition of sugar moieties) occurs via membrane-bound transferases.

    • Monosaccharides are added sequentially to the growing polysaccharide chain during transport to the Golgi apparatus.

    • Sulfation and iduronate synthesis occur before adding the next monosaccharide.

    • Final structure is extruded into the extracellular space (contributing to the extracellular matrix).

Synthesis of Glycoproteins:

  • Oligosaccharide Attachment:

    • Oligosaccharides are branched structures linked to proteins via two main types:

    • O-Linkages: Attach to serine or threonine residues (affecting protein structure and function).

    • N-Linkages: Attach to asparagine residues (modulating folding and stability).

Lysosomal Targeting:

  • Glycoprotein Tagging:

    • Lysosomal enzymes are glycoproteins tagged in the Golgi with Mannose-6-P (Man-6-P) (crucial marker).

    • Tagging directs glycoproteins to the lysosome (ensuring they reach their functional destination effectively).

I-Cell Disease:

  • Pathophysiology:

    • Caused by deficiency in the enzyme (N-acetylglucosamine-1-phosphate transferase) required to produce the Man-6-P tag.

    • Results in misaddressed lysosomal enzymes secreted into plasma (loss of function).

    • Accumulation of undegraded substrates forms inclusion bodies (severe cellular dysfunction).

    • Clinical presentation includes mental deterioration (cognitive decline) and skeletal deformities.

    • Life expectancy often less than 8 years due to disease progression.

Degradation of GAGs and Glycoproteins:

  • Lysosomal Digestion:

    • GAGs and glycoproteins are degraded in lysosomes by specific acid hydrolases (sequentially and efficiently).

    • Deficiency in any acid hydrolase leads to degradation halts (resulting in substrate accumulation).

    • Lysosomal Storage Diseases:

    • Conditions like mucopolysaccharidoses (due to accumulated GAG fragments causing damage).

    • Oligosaccharidoses (caused by the accumulation of branched oligosaccharides).

Mucopolysaccharidoses:

  • Overview:

    • Characterized by progressive accumulation of specific oligosaccharides (due to defective lysosomal enzymes).

    • Symptoms develop gradually (often unnoticed) and may appear normal at birth, but become pronounced later.

    • Affects multiple organs, leading to mental deficiency and physical deformities related to connective tissue dysfunction.

  • Specific Types:

    • Hunter Syndrome: X-linked condition with a spectrum of physical and mental symptoms.

    • Hurler Syndrome: Autosomal recessive disorder leading to severe physical health and developmental effects.

    • Sly Syndrome: Varying severity affecting organ systems differently (showing diverse clinical implications).